Chronic Hepatitis C Infection Clinical Trial
Official title:
A Phase I Trial of an Immunotherapy (HCVax™) in Chronic Hepatitis C Infected Patients
NCT number | NCT04318379 |
Other study ID # | GC002 |
Secondary ID | |
Status | Recruiting |
Phase | Phase 1 |
First received | |
Last updated | |
Start date | April 20, 2021 |
Est. completion date | December 2023 |
GC002 is a Phase I trial to evaluate the safety and the immune responses of a lentiviral based HCV immunotherapy (HCVax™) in chronic HCV patients.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | December 2023 |
Est. primary completion date | February 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility | Inclusion Criteria: 1. Documentation of chronic hepatitis C infection based on serum positivity for HCV RNA for at least 6 months interval. HCV genotype will be recorded. All genotypes will be eligible. 2. Patients who are not under DAA treatment. 3. Liver fibrosis (by Metavir stage F1 or F0) within one year of the screening visit, documenting extent of liver disease consistent with chronic hepatitis C with evidence of inflammation and/or fibrosis. Fibrosis scaling is based on an ultrasound based elastography (FibroScan, Echosen, Paris France) with cutoff of 7.5 kPa or liver biopsy. 4. Screening laboratory values within institutional normal range, with the exception of liver enzymes = 3 ULN and bilirubin <1.5 ULN, or judged to be not clinically significant by clinical investigator. 5. Ability and willingness of subject to give written informed consent. 6. Negative pregnancy test on the day prior to each vaccination. 7. Willingness to use adequate contraception by study participants. Subjects must agree not to participate in a conception process (e.g., active attempts to become pregnant or to impregnate, sperm donation, or in vitro fertilization), and if participating in sexual activity that could lead to pregnancy, subjects must use a form of contraception as listed below while on study vaccine and for 60 days after stopping study vaccine. Women without reproductive potential (i.e., have reached menopause or undergone hysterectomy, bilateral oophorectomy, or tubal ligation) or women whose male partner has undergone successful vasectomy with documented azoospermia or has documented azoospermia for any other reason, are eligible without requiring the use of contraception. Exclusion Criteria: 1. History of decompensated liver disease, including but not restricted to, portal hypertension as manifested by a known history of gastroesophageal varices, variceal bleeding, ascites or encephalopathy, histopathologic or clinical evidence of cirrhosis, hepatocellular carcinoma, or renal impairment consistent with hepatorenal syndrome; history of significant other non-HCV chronic liver disease, i.e. alcoholic hepatitis, autoimmune hepatitis. 2. History of hematologic disease (e.g., cryoglobulinemia, lymphoma), renal disease, dermatologic disease (e.g., lichen planus, porphyria cutanea tarda). 3. Seropositive for hepatitis B surface antigen (HBsAg) or HIV-1 antibody. 4. Autoimmune diseases or clinically serious cardiac, pulmonary, gastrointestinal, hepatic, renal or neurologic disease, which in the opinion of the investigator will compromise ability to participate in the study. 5. Previous receipt of any HCV experimental vaccine. 6. Pregnancy and breast-feeding. 7. Prior or current systemic cancer chemotherapy. 8. Investigational agents and immunomodulators (cyclosporine, hematological growth factors, systemic corticosteroids, interleukins or interferons) within 90 days prior to study entry. NOTE: Subjects may not be on antiretroviral agents not yet approved by the FDA as part of a clinical trial or expanded access program. 9. Anaphylaxis or allergy to vaccine components. 10. Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements. 11. Any other serious diseases other than HCV infection including current or recent (within 5 years) cancers. 12. Liver fibrosis with Metavir stage F2 or above. 13. Subjects with diabetes mellitus, who are at higher risk for more rapid progression of fibrosis. 14. Subjects who are immunocompromised or immunosuppressed due to disease or medications. 15. Subjects with any laboratory abnormalities Grade 3 or greater. 16. Women who are lactating. |
Country | Name | City | State |
---|---|---|---|
United States | Virginia Commonwealth University, Medical Center | Richmond | Virginia |
Lead Sponsor | Collaborator |
---|---|
GeneCure Biotechnologies |
United States,
Tung FY, Tung JK, Pallikkuth S, Pahwa S, Fischl MA. A therapeutic HIV-1 vaccine enhances anti-HIV-1 immune responses in patients under highly active antiretroviral therapy. Vaccine. 2016 Apr 27;34(19):2225-32. doi: 10.1016/j.vaccine.2016.03.021. Epub 2016 Mar 19. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To evaluate the safety of a therapeutic HCV vaccine in chronic HCV patients | Frequency and severity of adverse events, laboratory abnormalities, local and systemic reactogenicity signs and symptoms following vaccinations. | 40 weeks | |
Secondary | To evaluate the immunogenicity of a therapeutic HCV vaccine in chronic HCV patients | Magnitude of IFN-? & IL-2 producing CD4+ and CD8+ T cells to HCV core peptides pools at weeks 8, 16, and 24. | 40 weeks | |
Secondary | Virologic response | Sustained viral response (SVR) will be defined as negative HCV RNA result using an assay that has sensitivity of 25 IU or less per milliliter at 12 weeks after the end of vaccination. | 40 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02216422 -
A Study to Evaluate Chronic Hepatitis C Infection in Cirrhotic Adults With Genotype 1b Infection
|
Phase 3 | |
Completed |
NCT02219503 -
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis
|
Phase 3 | |
Completed |
NCT01700179 -
Evaluation of Safety, Tolerability, and Antiviral Activity of ACH-0143102 Plus Ribavirin In Treatment-naive Hepatitis C Virus Infection Genotype 1b Participants
|
Phase 1 | |
Completed |
NCT02486406 -
A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects
|
Phase 2/Phase 3 | |
Completed |
NCT01704755 -
A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis
|
Phase 3 | |
Completed |
NCT01225380 -
A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
|
Phase 2 | |
Completed |
NCT01221298 -
A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)
|
Phase 2 | |
Completed |
NCT01715415 -
A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults
|
Phase 3 | |
Completed |
NCT02065999 -
Surveillance for Antiviral Resistant Variants in Chronic Hepatitis C Patients
|
||
Completed |
NCT01716585 -
A Study to Evaluate Chronic Hepatitis C Infection
|
Phase 3 | |
Completed |
NCT01453075 -
Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and HSV-2 Infection (Phase I)
|
Phase 1 | |
Completed |
NCT01011166 -
Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin (MK-2355-004)
|
Phase 2 | |
Completed |
NCT00557583 -
Evaluation of Safety and Pharmacokinetics of Single Doses of VBY-376 in Healthy Adults
|
Phase 1 | |
Terminated |
NCT01586325 -
A Study of the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of JNJ-47910382 at Different Doses and Dose Regimens in Asian Genotype-1, Chronic, HCV-Infected Patients
|
Phase 1 | |
Recruiting |
NCT02583685 -
Switching Regimen in Treating Cirrhotic HCV GT1b Subjects
|
Phase 2 | |
Recruiting |
NCT02578693 -
Follow up of IFN Vs DAAs HCV SVR (IFDACS Study)
|
||
Completed |
NCT02576314 -
Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT3 Infected Patients
|
Phase 3 | |
Not yet recruiting |
NCT01835938 -
Clinical Investigation of Erlotinib as an HCV Entry Inhibitor
|
Phase 1/Phase 2 | |
Completed |
NCT01055821 -
Efficacy of the Therapeutic Vaccine TG4040 Combined With Pegylated Interferon and Ribavirin in Chronic HCV Patients
|
Phase 2 | |
Completed |
NCT01833533 -
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
|
Phase 3 |